The two most generally accepted methods to prove the safety of a generic version of a drug are to either repeat most of the chemistry, animal and human studies originally done, or to show that the drug performs comparably with the original brand name drug. This second option is called a "comparative bioavailability" study. During this type of study, volunteers are given the original drug, and then separately later the generic drug. The rates at which the drug is delivered to the patient (into their blood stream or otherwise absorbed) are measured to ensure they are the same. Because the same active ingredient is used the major concern is just that it delivers the common chemical(s) at the same rate so that they have the same effect. Please note that the methods that the manufacturers use may vary from country to country.
NAMI has recently started endorsing the Partnership
for Prescription Assistance , a new program that seeks to boost
enrollment in existing Patient Assistance Programs by helping consumers
identify and apply for programs for which they may be eligible. This
may be a good place to start if you are unfamiliar with Assistance
Programs that might work for you - however, we don't yet know how
successful the Partnership is at enrolling people in good programs,
or how much they may charge for their service. If anyone has experiences
to share about the Partnership for Prescription Assistance (good or
bad), please email the administration at: szwebmaster@.
Visit their website ( http:// ) or call 1-888-477-2669 if you are interested.
Free information sites about PAPs - include databases searchable by state, medication, or company name